Acetylon Pharmaceuticals, Inc. (Acetylon)

Oncology Corporate Profile

HQ Location

70 Fargo Street, Suite 205
Boston, MA 2210

Company Description

Acetylon Pharmaceuticals, Inc., based in Boston, Massachusetts, is a leader in the development of novel small molecule drugs targeting epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The Company_†_s epigenetic drug discovery platform has yielded a proprietary portfolio of optimized, orally-administered Class I and Class II histone deacetylase (HDAC) selective compounds. Alteration of HDAC regulation through selective HDAC inhibition is thought to be applicable to a broad range of diseases including cancer, sickle cell disease and beta-thalassemia, and autoimmune and neurodegenerative diseases. Acetylon_†_s lead drug candidate, ricolinostat (ACY-1215), is a selective HDAC6 inhibitor currently in Phase 1b clinical development for the treatment of multiple myeloma.

Website: Http://

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Acy-1215 + pomalidomide)histone deacetylase (HDAC) inhibitorMultiple MyelomaIICelgene
Acy-1215histone deacetylase (HDAC) inhibitorMultiple MyelomaIICelgene
Acy-1215 (+ bortezomib and dexamethasone)histone deacetylase (HDAC) inhibitorMultiple MyelomaICelgene
Acy-1215 (+ lenalidomide and dexamethasone)histone deacetylase (HDAC) inhibitorMultiple MyelomaICelgene

Pipeline image



Recent News Headlines

There are no news items to display